



Medi-Cal Rx

Now Available: CCS Panel Authority Policy Exclusions on the Medi-Cal Rx Approved NDC List

January 22, 2025

Background

The purpose of this alert is to inform pharmacy providers and prescribers that the [Medi-Cal Rx Approved NDC List](#) has been updated to reflect which drugs/products will be excluded (by NDC) from the California Children's Services (CCS) Panel Authority policy as part of Pediatric Integration. The effective date of the changes is January 31, 2025.

What Pharmacy Providers and Prescribers Need to Know

The [Medi-Cal Rx Approved NDC List](#) has been updated to include a detailed list of drugs/products that will be excluded (by NDC) from the CCS Panel Authority policy, beginning January 31, 2025. This list will be updated monthly. Drugs/products excluded from the CCS Panel Authority policy will require a prior authorization (PA), unless eligible to bypass Reject Code 75 under the continuation of therapy policy, as stated in the alert titled [Update: Important Policy Adjustment for Pediatric Integration](#).

What Pharmacy Providers and Prescribers Need to Do

CCS Paneled Providers are encouraged to review the [Medi-Cal Rx Approved NDC List](#) to determine which drugs/products will be subject to PA requirements beginning on January 31, 2025, and plan accordingly to ensure members' access to therapy.

For more information about Pediatric Integration, refer to the Pediatric Integration tab on the [Education & Outreach](#) page on the [Medi-Cal Rx Web Portal](#).

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.